title: Voriconazole does not affect the steady-state pharmacokinetics of digoxin.
abstract: OBJECTIVE
  Voriconazole is a triazole antifungal agent with potent fungicidal activity against Aspergillus species. Digoxin is a commonly prescribed cardiac glycoside with a narrow therapeutic index. This aim of this study was to investigate the effect of multiple-dose voriconazole on the steady-state pharmacokinetics of digoxin in healthy male volunteers.
  
  
  METHODS
  This was a double-blind, randomized, placebo-controlled, parallel-group study. All subjects received daily administration of oral digoxin for a total of 22 days (0.5 mg twice daily on day 1, 0.25 mg twice daily on day 2 and 0.25 mg once daily on days 3-22). In addition, on days 11-22 the subjects were randomized to receive either voriconazole (200 mg twice daily) or matching placebo.
  
  
  RESULTS
  Concomitant administration with voriconazole did not significantly alter the Cmax, AUCtau, tmax or CLR of digoxin at steady state. The ratios between groups for Cmax and AUCtau at day 22, corrected for baseline (day 10) were 109.8%[90% confidence interval (CI) 97.1, 124.1] and 100.5% (90% CI 91.4, 110.5), respectively. In addition, group mean Cmin values were similar in both treatment groups throughout the study. There were no significant differences between treatments with respect to the incidence of adverse events, all of which were classified as mild and transient in nature.
  
  
  CONCLUSIONS
  The steady-state pharmacokinetics of digoxin are not affected in a clinically relevant manner by the concomitant administration of voriconazole.
authors: Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, UK.
authors: Lynn
authors: L
authors: Purkins
authors: Nolan
authors: N
authors: Wood
authors: Diane
authors: D
authors: Kleinermans
authors: Don
authors: D
authors: Nichols
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D019540:Area Under Curve; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004077:Digoxin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans; D008297:Male; D010949:Plasma; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D002316:Cardiotonic Agents; D004338:Drug Combinations; D011743:Pyrimidines; D014230:Triazoles; D004077:Digoxin; D065819:Voriconazole